A Phase 1/2a Clinical Trial to Evaluate the Safety and Immunogenicity of ALVAC-HIV (vCP2438) and of MF59- or AS01B-adjuvanted Clade C Env Protein, in Healthy, HIV-uninfected Adult Participants
Phase of Trial: Phase I/II
Latest Information Update: 24 Apr 2018
At a glance
- Drugs HIV vaccine-vCP2438 (Primary)
- Indications HIV infections
- Focus Adverse reactions; Therapeutic Use
- 22 Jan 2018 Status changed from not yet recruiting to recruiting.
- 09 Jan 2018 Planned initiation date changed from 1 Dec 2017 to 1 Feb 2018.
- 18 Dec 2017 Planned initiation date changed from 18 Dec 2017 to 1 Dec 2017.